Transamination
- Compartment
- Cytosol + mitochondrion
- Main tissue
- Most tissues; esp. liver, muscle
- Rate-limiting
- Not flagged in the source
- Steps
- 5
Reaction steps
In source order, 5 total
-
1
Amino acid + enzyme-bound pyridoxal phosphate (E-PLP) → corresponding α-keto acid + enzyme-bound pyridoxamine phosphate (E-PMP)
› Notes
An aminotransferase (transaminase) forms an external aldimine with the amino acid and transfers its amino group to PLP. PLP (pyridoxal 5′-phosphate; vitamin B6) is essential; this reversible first half-reaction uses no ATP and no free ammonia is produced.
-
2
E-PMP + α-ketoglutarate → E-PLP + L-glutamate
› Notes
The same aminotransferase transfers the amino group from PMP to α-ketoglutarate, regenerating PLP and forming glutamate. This reversible second half-reaction completes the usual net reaction, amino acid + α-ketoglutarate ⇌ α-keto acid + glutamate.
-
3
L-alanine + α-ketoglutarate ⇌ pyruvate + L-glutamate
› Notes
Alanine aminotransferase (ALT/GPT) catalyzes this PLP-dependent, reversible reaction. In the glucose–alanine cycle, muscle exports alanine and liver converts it to pyruvate for gluconeogenesis while retaining the nitrogen as glutamate.
-
4
L-aspartate + α-ketoglutarate ⇌ oxaloacetate + L-glutamate
› Notes
Aspartate aminotransferase (AST/GOT) catalyzes this PLP-dependent, reversible reaction. In liver, aspartate supplies one of the two nitrogens of urea; mitochondrial AST also participates in the malate–aspartate shuttle.
-
5
Branched-chain amino acid + α-ketoglutarate ⇌ branched-chain α-keto acid + L-glutamate
Out Glutamate› Notes
Branched-chain amino acid aminotransferase (BCAT; PLP-dependent) initiates leucine, isoleucine, and valine catabolism. This reaction is prominent in skeletal muscle, which expresses BCAT but has relatively little hepatic BCAT activity.
Showing all 5 steps.
Regulation
What speeds each enzyme up and what slows it down
ALT (GPT)
Substrate availability; increased hepatic amino-acid flux
No dominant acute allosteric inhibitor
Insulin promotes amino-acid uptake and protein synthesis; glucagon/cortisol increase hepatic amino-acid catabolic capacity indirectly during fasting or stress
AST (GOT)
Substrate availability and cellular redox-linked shuttle demand
No dominant acute allosteric inhibitor
Primarily indirect regulation through nutritional state and tissue protein turnover
BCAT
Branched-chain amino acid availability
Product accumulation (branched-chain keto acids/glutamate)
Insulin favors BCAA uptake and protein synthesis in muscle; catabolic states favor net BCAA oxidation
Overview
Transamination is the reversible transfer of an α-amino group from an amino acid to an α-keto acid. It funnels nitrogen from most amino acids onto glutamate, while producing carbon skeletons that can enter energy metabolism, gluconeogenesis, ketogenesis, or biosynthetic pathways. The reactions do not release free ammonia and therefore provide a safe, readily reversible first stage of amino-nitrogen handling.
Cellular location
Aminotransferases are predominantly cytosolic, although important isoenzymes are mitochondrial; aspartate aminotransferase (AST/GOT) has both cytosolic and mitochondrial forms. They are active in essentially all tissues, with particularly high flux in liver, skeletal muscle, heart, kidney, and brain. Hepatocytes use transamination to channel amino nitrogen to glutamate and aspartate for urea production.
Net energetics
The canonical transamination has no direct ATP, GTP, NADH, FADH2, or NADPH cost or yield. It is near equilibrium; its direction is governed by substrate/product concentrations and by subsequent use of glutamate, aspartate, or the generated keto acid.
Clinical significance
Transamination links amino-acid turnover with central carbon metabolism and concentrates amino nitrogen on glutamate, the principal immediate donor for oxidative deamination. ALT is relatively enriched in hepatocytes, whereas AST is abundant in liver, cardiac muscle, skeletal muscle, and erythrocytes; increased plasma activity can indicate cellular injury but is not organ-specific in the case of AST. Severe vitamin B6 deficiency can reduce aminotransferase activity and disrupt neurotransmitter and amino-acid metabolism.
Recent literature
Live Europe PMC search
Europe PMC · fetched just now · sorted by publication date
-
1
Metabolic engineering of <i>Escherichia coli</i> for efficient production of d-phenylglycine.
Xiong Y, Shang Z, Lu L, Wang T, Cai G, Shen X, Sun X, Wang J, Yuan Q. · 2026-08-07
open access unreviewed -
2
Real-time NMR analysis of glutamine metabolism for screening anti-cancer agents in living cells.
Lei Y, Huang T, Chai X, Fan X, He S, Liu C, Liu M, Zhang X. · 2026-06-12
open access unreviewed -
3
<i>Akkermansia muciniphila</i> protects diabetes-associated cognitive decline by enhancing leucine catabolism and suppressing neuronal excessive mitophagy.
Ye X, Cai Q, Li Y, You M, Chen J, Pan Y, Zhu M, Lu Z, Chen S, Lin Y, Zhang W, Liu X, Wang Z, Hong G, Wu W, Zh… · 2026-09-30
open access unreviewed -
4
Branched-chain amino acids and gut microbiota: coregulation and impact on neurological function via the gut-brain axis.
Li Q, Fan B, Xiao Y, Zhang Z, Zhao S, Liao B, Zeng J, Shan X, Ye H, Wen Y, Zhang L, Guo H, Xiao F, Zhu H. · 2026-07-14
open access unreviewed -
5
<i>Lactiplantibacillus plantarum</i> <sup>WJL</sup> ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
Benoit B, Letourneau P, Verdier V, Viney A, Barnel C, Chikh K, Vitalis O, Jalabert A, Wagner S, Laiola M, Ale… · 2026-07-12
open access unreviewed -
6
Cardiovascular-kidney-metabolic syndrome through the lens of gut‑derived uremic toxins.
Xu C, Snelson M, Marques FZ. · 2026-06-15
cited 1× open access unreviewed -
7
Systems engineering of <i>Escherichia coli</i> for high-level hydroxytyrosol production.
Zuo J, Zhang S, Huang W, Liu J, Gao C, Hu GP, Song W, Li X, Wei W, Wu J, Liu L, Liu K, Xu N. · 2026-06-01
open access unreviewed -
8
Enhanced production of l-histidine in <i>Escherichia coli</i> through systematic metabolic engineering and CER controlled fermentation.
Zhang B, Liu X, Zhao T, Hao J, Wang Z, Xia M, Chen N, Wang X, Fan X. · 2026-05-25
open access unreviewed -
9
Heterologous expression of hydroxylase coupled with pathway optimization enables highly efficient ʟ-DOPA production in <i>Corynebacterium glutamicum</i>.
Jia M, Duan R, Jiang Y, Chu X, Wu X, Yang H, Ye B, Zhang B. · 2026-05-16
open access unreviewed -
10
OmniEdit: A unified CRISPR/Cas9 platform for precise genome engineering and strain optimization of the <i>Cordyceps militaris</i> cell factory.
Liu M, Chen S, Wang J, Meng G, Dong C. · 2026-05-17
open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.